Intravenous Iron Drugs Market Analysis, Market Size, Application Analysis, Regional Outlook, Competitive Strategies And Forecasts, 2015 To 2022

Iron is one of the most crucial elements required by the human body. It is one of the components of hemoglobin and transports oxygen throughout the body. High-molecular-weight iron dextran is the first iron product in the intravenous iron drug market. Hepcidin, Ferritin, Hemoglobin, and Transferrin are major molecules which are critical in the regulation and function of iron. Global intravenous drugs market is expected to witness a lucrative growth during the forecast period owing to increasing applications as a result of technological advancements in the intravenous iron drugs, development in intravenous iron drugs which help in restoring iron stores in patients having iron-deficiency anemia, with resultant improved functional capacity and increased hemoglobin levels; growing trends and developments in the intravenous iron drug market such as bundled payment system, increasing penetration in the gynecology market and novel product development, increasing number of dialysis patients in the global population, rising developments of safe and reliable intravenous drug administration  are developments expected to fuel growth of intravenous drug market throughout the forecast period. Furthermore, increasing need of iron in the body of woman during pregnancy in order to prevent anemia as well as improvement of other maternal and birth outcomes, increasing number of diabetic patients in the global population, rising awareness towards healthcare and personal care and increasing applications of IV drugs in the diagnosis of various diseases such as anemia, kidney diseases and hypertension are applications further expected to boost growth of intravenous drugs market in the next seven years.

The global intravenous iron drugs market is segmented on the basis of therapeutic applications and product type. Product types include iron sucrose, low molecular weight iron dextran, ferric carboxyl maltose and ferric gluconate. In 2014, ferric gluconate accounted for the largest market share of the intravenous iron drug market. However, ferric carboxyl maltose segment is expected to grow at a significant rate due to its increasing application in drug discovery processes, reduced cost and superior performance. Furthermore, therapeutic application segment in the intravenous iron drugs market is divided into chronic heart failures, surgeries, gynecology, oncology, nephrology and gastroenterology. Nephrology accounted for the largest market share in 2014 owing to its increasing use in intravenous iron drugs and therapies. While chronic heart failures is expected to be the fastest growing segment owing to rising number of patients suffering from heart related disorders. Rising incidents of chronic kidney diseases, increasing need to address iron deficiency anemia in gastroenterology, gynecology and oncology, increasing pool of patients with high rate of unresponsive oral therapy, rising global medicine and healthcare expenditure and high-sensitivity, accuracy, easy, and convenient access of intravenous iron dosages are expected to drive demand of intravenous iron drug market through to the 2022.

The geographical analysis of intravenous iron drugs market divides it into North America, Europe, Asia-Pacific, Latin America and MEA. In 2014, North America accounted for the largest market share owing to increasing application of intravenous iron drugs in cancer research, increasing adoption of low cost and compact intravenous iron drugs in clinical diagnostics and research laboratories and quality infrastructure for laboratory and clinical research. Emerging economies such as China and India in the Asia Pacific region are expected to grow at a significant rate. This expected growth is attributed for by increasing government and corporate investment in the biotechnology sector and biopharmaceutical industry, increasing development and production of new biologics, vaccines, and drugs, expanding medical treatment for infectious and chronic diseases, increasing median age of the population, huge number of investment opportunities in these immature markets, increasing number of diagnostics laboratories in the region and increasing focus on attracting international and domestic players in the market. The global intravenous iron drugs market is highly competitive owing to emergence of new entrants in the market and the presence of well established firms. The key participants in the Intravenous iron drugs market are Rockwell Medical Technologies, Inc., Sanofi, Actavis, Inc., Luitpold Pharmaceuticals, Inc., Galenica Ltd., KGaA, Vifor Pharma Ltd., Fresenius Medical Care AG & Co., American Regent Inc., Pharmacosmos A/S, and AMAG Pharmaceuticals Inc.